Over a 48-week trial in adults with obesity but no diabetes, the highest tested dose of 12 mg once weekly produced an average 24.2% reduction in body weight , compared with just over 2% in the placebo group
Both terms are associated with the next frontier of incretin-based metabolic therapies, moving beyond the well-established GLP-1 and GIP pathways
Glucagon receptor antagonism and lipid metabolism. Diabetes Obes Metab , 2016
Most patients begin seeing results within the first 4-8 weeks
As with any prescription medication, tirzepatide may carry risks and side effects
Skip Supplements, Which Wont Help With Weight Loss Maintenance A new wave of supplements, each claiming to be natures Ozempic, has sprung up during the initial GLP-1 craze